A blood test, prostate-specific antigen (PSA), and the concept of doubling Oligomycin A chemical structure time (PSADT) and PSA kinetics are being used as proxies of disease speed of progression. Studies using these proxies report conflicting results. These studies cast doubts on the current rules for stopping AS and recent research

concludes that PSADT and PSA kinetics are unreliable triggers for intervention in an AS program. These findings are consistent with stochastic processes being analyzed as if they were “”deterministic”" (i.e., current models measure disease progression by PSA’s evolution assuming it to be deterministic). A model that best describes PSA evolution is a pre-requisite to the establishment of decision criteria for abandoning AS. This paper suggests modeling PSA evolutions and kinetics as stochastic processes. Consequently, triggers for stopping AS may be different than PSADT and can result in substantially different recommendations, which are likely to have significant impact on patients and the healthcare system. (c) 2011 Elsevier Ltd. Verteporfin All rights reserved.”
“The rapid development of high-yielding and robust manufacturing processes for monoclonal antibodies is an area of significant focus in the biopharmaceutical landscape. Advances in mammalian cell culture have taken titers to beyond the 5 g/l mark. Platform

approaches to downstream process development have become widely established. Continuous evolution of these platforms is occurring as experience with a wider range of products is accrued. The increased cell culture productivity has shifted the attention of bioprocess development to operations downstream of the production bioreactor. This has rejuvenated interest in the use of non-chromatographic separation processes. Here, we review the current state-of-the-art industrial isometheptene production processes, focusing on downstream technologies, for antibodies and antibody-related products and discuss future avenues for evolution.”
“A peptide-based 2-D liquid phase fractionation (PF2D) system was used in a quantitative proteomic analysis of hepatocellular carcinoma. 2-D liquid maps of peptide specimens showed better

resolution than those of proteins, leading to the identification of differentially expressed proteins. Peptide-based PF2D gave well-matched theoretical and experimental pI values and was proven to be a very efficient and versatile analytical tool for both large-scale profiling and quantification of phosphoproteins in disease biomarker discovery.”
“Voluntary, self-initiated actions are preceded by slowly increasing neural activity in pre-motor regions of the brain, beginning up to 2s before the onset of muscle movement. This activity is commonly seen in the scalp-recorded readiness potential, and is an index of movement preparation involving both motor programming and non-motor or cognitive processes such as attention.